Purevax RCP

Search

Drugs Alphabetically

A B C D E F G
H I J K L M N
O P Q R S T U
V W X Y Z

Summary for the public
Authorisation details
Product Characteristics:
Name Of The Veterinary Medicinal Product
Qualitative And Quantitative Composition
Pharmaceutical Form
Clinical Particulars
Target species
Indications for use
Contraindications
Special warnings
Special precautions for use
Adverse reactions (frequency and seriousness)
Use during pregnancy, lactation or lay
Interaction with other medicinal products and other forms of interaction
Amounts to be administered and administration route
Overdose (symptoms, emergency procedures, antidotes)
Withdrawal period(s)
Pharmacological Properties
Pharmaceutical Particulars
Marketing Authorisation Holder
Marketing Authorisation Number(s)
Date Of First Authorisation / Renewal Of The Authorisation
Date Of Revision Of The Text
Advertise Here
Feedback

Summary for the public

What is Purevax RCP?

Purevax RCP is a vaccine containing the following active substances:

- attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain),
- inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains),
- attenuated feline panleucopenia virus (PLI IV).

Purevax RCP is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.

What is Purevax RCP used for?

Purevax RCP is used to vaccinate cats from the age of 8 weeks against the following diseases:

- feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus),
- feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus),
- feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus).

The vaccine helps to reduce the symptoms of the diseases. It also helps to reduce viral excretion in case of calicivirus infection. It can also prevent death due to panleucopenia.

After Purevax RCP has been made up, 1 ml is injected under the skin. The first injection should be given in cats aged at least eight weeks, with a second injection three to four weeks later. If the cat has high levels of antibodies inherited from the mother, the first vaccination should be delayed until 12 weeks of age. The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis and calicivirosis, and every three years for panleucopenia.

How does Purevax RCP work?

Purevax RCP is a vaccine. Vaccines work by 'teaching' the immune system (the body's natural defences) how to defend itself against diseases. Purevax RCP contains small amounts of weakened or killed viruses that cause the diseases listed above.

When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as 'foreign' and makes antibodies against them. In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses. The antibodies will help to protect against the diseases caused by these viruses. When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.

How has Purevax RCP been studied?

The effectiveness of Purevax RCP has been studied in several trials in laboratory conditions where cats were vaccinated and infected with virulent herpesvirus,

calicivirus or parvovirus. In the field, the studies of Purevax RCP looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection). The studies included young and adult cats of various breeds, but not young kittens. The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine.

What benefit has Purevax RCP shown during the studies?

In laboratory conditions Purevax RCP was demonstrated to provide protection against the diseases listed above. In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus, calicivirus infection, and feline panleucopenia viruses. In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus, calicivirus infection and feline panleucopenia remained stable at a high level or increased slightly.

What is the risk associated with Purevax RCP?

Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days. There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks. For a full list of the side-effects reported with Purevax RCP, see the Package Leaflet. Purevax RCP should not be used in pregnant cats.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

In case of accidental self-injection seek medical advice immediately and show the Package Leaflet or the label to the doctor.

Why has Purevax RCP been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RCP exceed the risks for the active immunisation of cats aged eight weeks or older against the diseases listed above, and recommended that Purevax RCP be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.

Other information about Purevax RCP

The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RCP to MERIAL on 23 February 2005.

Authorisation details

Name: Purevax RCP
EMEA Product number: EMEA/V/C/000090
Active substance: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline Calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV)
INN or common name: Vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia
Species: Cats
ATCvet Code: QI06AH
Marketing Authorisation Holder: Merial
Revision: 7
Date of issue of Market Authorisation valid throughout the European Union: 23/02/2005
Contact address:
Merial
29 avenue Tony Garnier
69007 Lyon
France

Product Characteristics

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

Purevax RCP lyophilisate and solvent for suspension for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Per dose of 1 ml:

Lyophilisate :
Active substances:
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) .....$\geq 10^{4.9}$ $CCID_{50}$
Inactivated feline Calicivirosis antigens (FCV 431 and G1 strains) .....≥ 2.0 ELISA U.
Attenuated feline panleucopenia virus (PLI IV) .....$\geq 10^{3.5}$ $CCID_{50}$
Excipient:
Gentamicin, at most..... 16.5 µg

Solvent:

Water for injection.....q.s. 1 ml

1: cell culture infective dose 50%

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Lyophilisate and solvent for suspension for injection.

4. CLINICAL PARTICULARS

4.1 Target species

Cats.

4.2 Indications for use

Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs and excretion,
- against feline panleucopenia to prevent mortality and clinical signs.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis and calicivirus, and 3 years for panleucopenia component.

4.3 Contraindications

Do not use in pregnant animals.
The use is not recommended during lactation.

4.4 Special warnings

None.

4.5 Special precautions for use

Special precautions for use in animals

Use only in healthy animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days). A local reaction may occur (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most.
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.

4.7 Use during pregnancy, lactation or lay

Do not use in pregnant animals.
The use is not recommended during lactation.

4.8 Interaction with other medicinal products and other forms of interaction

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.

4.9 Amounts to be administered and administration route

Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule:

Primary vaccination course:
- first injection: from 8 weeks of age,
- second injection: 3 to 4 weeks later.

.

Where high levels of maternal antibodies against R, C or P components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

Revaccination:
- for all components one year after primo-vaccination,
- then every year for the rhinotracheitis and calicivirosis components, and every three years for the panleucopenia component.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No effects other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.

4.11 Withdrawalperiod(s)

Not applicable.

5. IMMUNOLOGICAL PROPERTIES

ATC Vet Code: QI06AH09

Vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, and feline panleucopenia virus.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose
Sorbitol
Dextran 40
Casein hydrolysate
Collagen hydrolysate
Dipotassium phosphate
Potassium dihydrogen phosphate
Potassium hydroxide
Sodium chloride
Disodium hydrogen orthophosphate
Monopotassium phosphate anhydrous

6.2 Incompatibilities

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administrated with Merial non-adjuvanted vaccine against feline leukaemia

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale:18 months.
Shelf life after reconstitution: use immediately after reconstitution

6.4. Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

6.5 Nature and composition of immediate packaging

Type I glass bottle containing 1 dose of lyophilisate and type I glass bottle containing 1 ml of solvent, both closed with a butyl elastomer closure and sealed with an aluminium cap.
Pack containing 10 bottles of 1 dose of lyophilisate and 10 bottles of 1 ml of solvent
Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

7. MARKETING AUTHORISATION HOLDER

MERIAL
29, avenue Tony Garnier
69007 LYON
FRANCE

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/04/052/001-002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 23/02/2005
Date of last renewal: 25/01/2010

10. DATE OF REVISION OF THE TEXT

25/01/2010

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

ANNEX II

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE

C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE

D. STATEMENT OF THE MRLs

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) of the biological active substance(s)

Merial
Laboratory of Lyon Porte des Alpes
Rue de l'aviation
69800 SAINT-PRIEST
France

Merial
Laboratory of Lyon Gerland
254, Avenue Marcel Mérieux
69007 LYON
France

Name and address of the manufacturer responsible for batch release

Merial
Laboratory of Lyon Porte des Alpes
Rue de l'aviation
69800 SAINT-PRIEST
France

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE

To be supplied only on veterinary prescription.

C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT

Not applicable

D. STATEMENT OF THE MRLs

B. STATEMENT OF THE MRLS

Not applicable

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Pack of 10 bottles of lyophilisate and 10 bottles of solvent
Pack of 50 bottles of lyophilisate and 50 bottles of solvent

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

Purevax RCP, lyophilisate and solvent for suspension for injection

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Per dose of 1 ml:

FHV (F2 strain) ..... $\geq 10^{4.9}$ $CCID_{50}$

FCV (431 and G1 strains) ..... ≥ 2.0 ELISA U.
FPV (PLI IV)..... ≥ $10^{3.5}$ $CCID_{50}$
Gentamicin, at most..... 16.5 µg

3. PHARMACEUTICAL FORM

Lyophilisate and solvent for suspension for injection.

4. PACKAGE SIZE

Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml)
Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)

5. TARGET SPECIES

Cats.

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP (mm/yyyy)
Use immediately after reconstitution.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN"

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MERIAL
29, avenue Tony Garnier
F-69007 LYON
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/04/052/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml)
EU/2/04/052/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)

17. MANUFACTURER'S BATCH NUMBER

Lot

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Lyophilisate bottle

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

Purevax RCP lyophilisate for injection

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Read the package leaflet before use.

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 dose

4. ROUTE(S) OF ADMINISTRATION

Subcutaneous use.

5. WITHDRAWAL PERIOD

6. BATCH NUMBER

Lot

7. EXPIRY DATE

EXP (mm/yyyy)

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Solvent bottle

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

Purevax RCP solvent

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Read the package leaflet before use.

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 dose

4. ROUTE(S) OF ADMINISTRATION

Subcutaneous use.

5. WITHDRAWAL PERIOD

6. BATCH NUMBER

Lot

7. EXPIRY DATE

EXP (mm/yyyy)

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET FOR:

Purevax RCP
lyophilisate and solvent for suspension for injection.

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
MERIAL
29, avenue Tony Garnier
F-69007 Lyon
France

Manufacturer for the batch release:
MERIAL
Laboratoire Porte des Alpes
Rue de l'aviation
F-69800 Saint-Priest
France

2. NAME OF VETERINARY THE MEDICINAL PRODUCT

Purevax RCP lyophilisate and solvent for suspension for injection.

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Per 1-ml dose:

Lyophilisate :
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) .....$\geq 10^{4.9}$ $CCID_{50}$

Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains) .....≥ 2.0 ELISA U.

Attenuated feline panleucopenia virus (FPLPV) ..... ≥ $10^{3.5}$ $CCID_{50}$[1]

Excipient:
Gentamicin, at most..... 16.5 µg

Solvent:
Water for injectionq.s. 1 ml

1: cell culture infective dose 50%

4. INDICATION(S)

Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs and excretion,
- against feline panleucopenia to prevent mortality and clinical signs.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis and calicivirus, and 3 years for panleucopenia component.

5. CONTRAINDICATIONS

Do not use in pregnant animals.
The use is not recommended during lactation

6. ADVERSE REACTIONS

In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days). A local reaction may occur (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most.
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Cats.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule:

Primary vaccination course:
- first injection: from 8 weeks of age,
- second injection: 3 to 4 weeks later.

Where high levels of maternal antibodies against R, C or P components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

Revaccination:
- for all components one year after the primary vaccination course,
- then every year for the rhinotracheitis and calicivirosis components, and every three years for the panleucopenia component.

9. ADVICE ON CORRECT ADMINISTRATION

Use immediately after reconstitution.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administrated with Merial non-adjuvanted vaccine against feline leukaemia and/or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.
Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

12. SPECIAL WARNING(S)

Use only in healthy animals.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Do not use in pregnant animals.
The use is not recommended during lactation.

No effect other than those already mentioned in section "Adverse reactions" have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

25/01/2010

Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/

15. OTHER INFORMATION

Pack containing 10 bottles of 1 dose of lyophilisate and 10 bottles of 1 ml of solvent
Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent
Not all pack sizes may be marketed.

To be supplied only on veterinary prescription.